Lupus & Connective Tissue Diseases

MD IQ

Conference Coverage

Remibrutinib safe for Sjögren’s in phase 2

Results show the Bruton tyrosine kinase inhibitor has potential to become the first effective oral disease-modifying therapy for Sjögren syndrome...

Pages